Theranica Develop Innovative Wearable Patch To Fight Migraines

Theranica Develop Innovative Wearable Patch To Fight Migraines

Migraine is the third most common disease in the world, affecting around 1 billion people worldwide. While the exact cause is still unknown, it is a complex conditions with a wide variety of symptoms, including a painful headache that can last for days. This not only interfere with daily routines, but seriously degrade quality of life. As a result, migraine is ranked as one of the most disabling diseases globally, responsible for 2.9% of all years of life lost to disability, and the leading cause of disability among neurological disorders.

The Israel-based startup Theranica is combining neuromodulation therapy with modern wireless technology to develop wearable solutions that address various medical conditions and disease states. Their first product is a migraine-relief patch called Nerivio, offering an affordable, non-invasive and non-pharmacological medical therapy. The technology is based on what is called Diffuse Noxious Inhibitory Controls, a phenomenon where the response to a pain stimulus is inhibited by a second pain stimulus. The wearable patch is simply attached to the arm, and the generated electrical pulses stimulate sensory nerves under the skin, resulting in pain relief. The patch is launched and controlled using a complementary app on a smartphone or tablet, providing a personalized pain-relief program that can be used by anyone, at any time, everywhere.

The most common remedy for migraine headaches is medication, however there can be significant side effects. As a result, many medications are not recommended for certain patient groups, such as children and pregnant women. Theranica has developed a safe and easy to use solution that could dramatically change how patients manage their migraines. A pilot study of the startup’s technology has shown promising results in terms of clinical efficacy and safety, and may ease migraine pain as well as pharmacological options. The technology provide personalized, portable and affordable care, allowing patients to take back control of their daily routines. It could increasing access to care and improve quality of life for millions of people worldwide who suffer from migraines.

Theranica was founded in 2016 by Alon Ironi, Ronen Jashek, Slava Barabash and Shimon Eckhouse with the vision of developing electroceuticals to address prevalent medical conditions and diseases. In July 2017, they announced the closing of a round A of financing, raising $6 million. The round was led by Lightspeed Venture Partners, with other investors including LionBird Venture Capital and Corundum Open Innovation. The funds will be used to move past the regulatory stage and mass produce the Nerivio patch, and they are now about to commence a multi-center clinical trial in Israel and the US.